Home>Topics>Stocks>NuVasive

NuVasive NUVA

  1. All
  2. Commentary
  3. Headlines
    1. Bernanke’s Santa Claus Cheer

      Headlines

      Fri, 27 Dec 2013

      NuVasive 's fortunes are bound to spinal fusion.

    2. NuVasive ( NUVA ): Q1 EPS of $0.26 beats by $0.04. Revenue of $159.5M (+5.2% Y/Y) beats by $2.06M. (PR)

      Headlines

      Tue, 30 Apr 2013

      NuVasive ( NUVA ): Q1 EPS of $0.26 beats by $0.04 . Revenue of $159.5M (+5.2% Y/Y) beats by $2.06M . ( PR ) Post your comment!

    3. Closing the DOJ Investigation of INFUSE Comes as Good News to Medtronic

      Commentary

      Wed, 16 May 2012

      treatment. Additionally, smaller competitors such as NuVasive NUVA have introduced new biologic products that compete with ..... be bundled with its hardware and instrument systems, NuVasive has been able to attract more spinal surgeons to embrace

    4. Dropping Coverage of NuVasive

      Commentary

      Fri, 19 Aug 2011

      We are no longer providing equity research on NuVasive NUVA . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.

    5. NuVasive to Refinance 2013 Convertibles with New Issue

      Commentary

      Wed, 22 Jun 2011

      NuVasive NUVA announced its intentions to issue $325 ..... issue. In terms of valuation, we think NuVasive shares are about fairly valued, so we ..... a potential credit-sensitive play at NuVasive . We've seen 10-year issues of BBB

    6. In-line Fourth Quarter for NuVasive , but Uncertainty Remains in Spine Market

      Commentary

      Fri, 25 Feb 2011

      NuVasive NUVA reported fourth-quarter earnings that ..... commercial insurers still provide coverage for NuVasive 's lateral procedure though, after deeming ..... and long-term assumptions. We think NuVasive will have to largely generate growth in

    7. NuVasive Under Review

      Commentary

      Tue, 7 Dec 2010

      We are placing NuVasive NUVA under review as we update our valuation. As we noted previously, we will moderately cut our fair value estimate due to a decrease

    8. Procedural Delays, Worries About Spinal Market Slam NuVasive

      Commentary

      Fri, 29 Oct 2010

      NuVasive NUVA reported disappointing projections for ..... fourth quarter, which traditionally is NuVasive 's strong quarter. We will lower our ..... moderate cut in our fair value estimate. NuVasive posted decent third-quarter results

    9. Strong 2Q, but Worries for NuVasive

      Commentary

      Mon, 30 Aug 2010

      NuVasive NUVA put in a strong second quarter and increased ..... margin biologics and international sales. NuVasive 's operating expenses climbed to $90 ..... of 29% over the prior-year period. NuVasive invested heavily in expanding its international

    10. New Credit Rating: NuVasive

      Commentary

      Wed, 12 May 2010

      initiating our issuer credit rating for NuVasive NUVA at BBB - , reflecting its improving ..... position and cash flow trends . NuVasive 's Maximum Access Surgery platform ..... new approach , so far . In fact , NuVasive has carved out a nice niche in

    « Prev123Next »
    Content Partners